{
    "nctId": "NCT00272987",
    "briefTitle": "ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib",
    "officialTitle": "A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 63,
    "primaryOutcomeMeasure": "Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Histologically confirmed invasive breast cancer with stage IV disease\n* If trastuzumab was administered in the adjuvant setting, \\>12 months must have elapsed since discontinuation of trastuzumab therapy\n* If a taxane was administered in the neoadjuvant or adjuvant setting, progression must have occurred \u226512 months after completion of this treatment\n* Had tumors that overexpress ErbB2 defined as either: 3+ by IHC OR c-erbB2 gene amplification by FISH OR 0, 1+, 2+ by IHC and c-erbB2 gene amplification by FISH.\n* Patients must have tumor tissue available for central testing, and must have Measurable lesion(s) according to RECIST\n* Subjects must be females of at least 18 years Non-childbearing potential or Childbearing potential but using adequate contraception\n* Radiotherapy to a limited area other than the sole site of measurable and assessable disease is allowed; however, patients must have completed treatment and recovered from all acute treatment-related toxicities prior to administration of the first dose of study medication\n* Bisphosphonate therapy for bone metastases is allowed; however, treatment must be initiated prior to the first dose of randomized therapy. Prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1\n* For those patients whose disease is estrogen receptor positive+ and/or progesterone receptor + one the following criteria should be met: Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases) or Rapidly progressing/life threatening disease, as determined by the investigator or Patients who received hormonal therapy and are no longer benefiting from this therapy;\n* Able to swallow and retain oral medication\n* Cardiac ejection fraction within institutional range of normal\n* Patient must have adequate organ function\n\nExclusion criteria:\n\n* Pregnant or lactating females;\n* Received prior chemotherapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for metastatic disease, prior hormonal therapy is permitted but must be discontinued a minimum of 7 days prior to randomization;\n* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Patients with ulcerative colitis are also excluded;\n* History of other malignancy; however, patients who have been disease-free for five years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;\n* Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical disorder that would interfere with the patient's safety;\n* Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;\n* Peripheral neuropathy of Grade 2 or greater;\n* Active or uncontrolled infection;\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;\n* Known history of uncontrolled or symptomatic angina, arrhythmias, conduction abnormalities or congestive heart failure;\n* Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis;\n* Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy);\n* Concurrent treatment with an investigational agent or participation in another clinical trial;\n* Concurrent treatment with any medication on the prohibited medications list.\n* Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of treatment. Hormonal therapy needs to be discontinued at least 7 days before the first dose of treatment.\n* Prior therapy with an ErbB2 inhibitor, other than trastuzumab in the adjuvant setting;\n* A known immediate or delayed hypersensitivity reaction to drugs chemically related to lapatinib or excipients;\n* A known immediate or delayed hypersensitivity reaction to drugs chemically related to paclitaxel or excipients;\n* A known immediate or delayed hypersensitivity reaction to drugs chemically related to trastuzumab or excipients;\n* Non compliance with any of the screening procedures",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}